Viewing Study NCT01379534

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:18 AM
Ignite Modification Date: 2026-05-09 @ 3:22 AM
Study NCT ID: NCT01379534
Status: COMPLETED
Last Update Posted: 2015-05-20
First Post: 2011-06-06
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumors and Advanced Endometrial Cancer View
None Endometrial Cancer View
None Second-line Treatment View
None VEGF View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Solid tumors, View
None advanced endometrial cancer, View
None Endometrial Cancer, View
None Second-line treatment, View
None VEGF, View
None Neoplasms, View
None Endometrial Neoplasms, View
None Uterine Neoplasms, View
None Female Genital Neoplasms, View
None Cancer, View
None Carcinoma, View
None Uterine Diseases, View
None Female Genital Diseases, View
None Tumors, View
None Oral Administration, View
None Capsules, View
None Tablets, View
None CHIR258, View
None CHIR-258, View
None CHIR 258, View
None TKI258, View
None TKI-258, View
None TKI 258 View